Subscribe to our Newsletters !!
In tortoises, longevity is an astonishing trait. N
When we picture cutting-edge science, we tend to c
New Delhi – August 23, 2025 – The Association
This year, the Hamburg based life sciences company
Cipla Limited (BSE: 5
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
Zydus Cadila has obtained final acceptance by the US Food and Drug Administration (USFDA) to advertise Cisatracurium Besylate Injection USP at the potency of 20 milligrams (base)/10 mL (two mg/mL) multiple-dose vial, Cadila Healthcare stated in a regulatory filing on Wednesday.
The drug will be produced in Liva plant of Cadila Healthcare Ltd..
Zydus Cadila is Part of this Cadila Healthcare group.
The team currently has 297 approvals and has up to now registered over 390 abbreviated new drug applications (ANDAs) because the initiation of the filing procedure from FY 2003-04.
Shares of Cadila Healthcare, the listed entity of this group, were trading at Rs 377.60 apiece on BSE, 0.15 percent lower from their previous closure.
